Latest Health News

Forbidden Foods Limited has raised $1 million to boost inventory for its Blue Dinosaur and Oat Milk Goodness brands, following a remarkable 104% jump in quarterly sales.

LGI Limited reports a solid H1 FY25 performance with modest revenue growth and increased EBITDA, driven by expanded biogas flows and carbon abatement activities. The company confirms a positive outlook with a 12-15% underlying EBITDA growth forecast for FY25.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

AMP Limited’s FY24 Data Pack outlines a solid underlying profit performance despite headwinds, with key insights into its banking, platform, and wealth management divisions.

Civmec’s 1H FY25 results reveal robust revenue growth and a strong balance sheet, underpinned by a diversified project pipeline and strategic moves into naval shipbuilding and material handling equipment manufacturing.

HealthCo Healthcare & Wellness REIT reported a solid 5% increase in Funds From Operations (FFO) and Distribution Per Unit (DPU) for the first half of FY25, underpinned by stable asset valuations and a robust healthcare portfolio.

Cochlear Limited has announced a fully franked dividend of AUD 2.15 per share for the six months ending December 2024, payable in multiple currencies on April 14, 2025.

Unibail-Rodamco-Westfield delivered robust FY-2024 results with a 7% rise in like-for-like EBITDA and adjusted recurring EPS surpassing guidance, supported by strong retail and convention business performance. The company also announced a 40% increase in its proposed dividend, reflecting confidence in its financial health and strategic asset management.

Prophecy International Holdings has posted a record half-year revenue of $11.6 million for H1 FY25, driven by strong demand for its AI-enabled cybersecurity and data integration products. The company’s transition to subscription models and expansion into new global markets underpin a positive outlook.

Pro Medicus has delivered a record first half in FY25, driven by strong revenue growth, major contract wins, and successful implementations that position it well for future expansion.

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.25 per share for the six months ending December 2024, signaling continued shareholder returns without the need for external approvals.

Pro Medicus Limited has delivered a record interim profit of $51.7 million, boosted by major North American contract wins and strong margin expansion.